BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

open access version
 

Discussion

The main findings in this study are that: (1) most patients with newly diagnosed ovarian cancer accept germline BRCA1/2 testing, with significantly lower uptake among breast cancer patients; (2) there is a high prevalence of BRCA1/2 mutation carriers in the group of ovarian cancer patients; (3) all patients who were identified with a pathogenic BRCA1/2 variant fulfill our current clinical criteria for diagnostic BRCA1/2 testing; and (4) the level of anxiety and depression symptoms in the participants at inclusion was comparable to what can be found in cancer patients in general.^{28, 29}